Discover 495 paid clinical trials in Louisville, Kentucky. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Get alerts for new trials in your area by subscribing now
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
for
Solid Tumors, Hematologic Malignancies
Location: Louisville KY, Nashville TN, Paducah KY, Chicago IL,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT03486873
Phase3, Recruiting
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
for
Advanced Lung Non-Small Cell Carcinoma,
Location: Louisville KY, Lexington KY, Franklin OH,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 70+
Code: NCT06096844
Phase3, Recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
for
Endometrial Cancer
Location: Louisville KY, Detroit MI, Pittsburgh PA, Augusta GA,
Sponsor: Iovance Biotherapeutics, Inc.
Sex: Female
Age: 18 - 70
Code: NCT06481592
Phase2, Recruiting
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Long-term Effects of Acoltremon vs. Control in Dry Eye Disease
for
Dry Eye
Location: Louisville KY
Sponsor: The Eye Care Institute
Sex: All
Age: 18+
Code: NCT07659626
Recruiting
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
for
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Location: Jeffersonville IN, Lexington KY, Cincinnati OH,
Sponsor: Ferring Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06510374
Phase3, Recruiting
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients